Patterns of lipid changes among type 2 diabetes patients in Sudan

Eastern Mediterranean Health Journal

Volumn 14, Issue 2, 2008, Pages 314-324

  Elnasri, H A ^a   Ahmed, Awad M ^a  

^a University of Bahr Elghazal   (Sudan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE DURATION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; RISK FACTOR; SEX DIFFERENCE; SUDAN;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; OBESITY; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION; SUDAN; TRIGLYCERIDES;

EID: 45849117276     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Goldberg IJ. Diabetic dyslipidaemia: causes and consequences. Journal of clinical endocrinology and metabolism, 2001, 8(3):965-71.
2. O'Brien T, Nguyen TT, Zimmerman BR. Hyperlipidemia and diabetes mellitus. Mayo Clinic proceedings, 1998, 73:969-76.
3. Colhoun HM et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 364:685-98.
4. Taskinen MR. Diabetic dyslipidaemia. Atherosclerosis. Supplements, 2002, 3(1):47-51.
5. Akbar DH, Ahmed MM, Algambi AA. Cardiovascular risk factors in Saudi and non-Saudi diabetics. Saudi medical journal, 2003, 24(6):686-7.
6. Al Muhtaseb N et al. Lipoproteins and apolipoproteins in young non obese Arab women with NIDDM treated with insulin. Diabetes care, 1989, 12:325-31.
7. Ahmed SAM, Idris ATM, El Mahdi EM. The levels of lipoproteins in Sudanese diabetics. Sudan medical journal, 1993, 33:1-12.
8. US Department of Health and Human Services. Physical activity and health. A report of the Surgeon General. Atlanta, Georgia, Centers for Diseases Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996:23-31.
9. Harris MI. Hypercholesterolemia in diabetes and glucose intolerance in the U.S. population. Diabetes care, 1991, 14:366-74.
10. Akanji AO. Diabetic dyslipidaemia in Kuwait. Medical principles and practice, 2002, 11:47-55.
11. Erasmus RT, Olujeopa O, Adelowo O. Correlation between glycosylated haemoglobin and serum lipids. Central African journal of medicine, 1987, 32:231-6.
12. UK Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM: effects of age and gender. Diabetes care, 1997, 20:1683-7.
13. Abbate SL, Brunzell JD. Pathophysiology of hyperlipidemia in diabetes. Journal of cardiovascular pharmacology, 1990, 16: S1-7.
14. Packard C, Nunn A, Hobbs R. High density lipoprotein: guardian of the vascular system? International journal of clinical practice, 2002, 56:761-71.
15. Horowitz BS et al. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. Journal of clinical investigation, 1993, 91(4):1743-52.
16. Laakso M. Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus. Lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus. Journal of diabetes and its complications, 1997, 11:137-41.
17. Sparks JD, Sparks CE. Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. Journal of biological chemistry, 1990, 265(15):8854-62.
18. Erasmus RT et al. Plasma HDL cholesterol, triglyceride and total cholesterol levels in non-insulin treated Nigerian diabetics. Tropical and geographical medicine, 1989, 41:238-41.
19. Nau DP, Mallya U. Sex disparity in the management of dyslipidemia among patients with type 2 diabetes mellitus in a managed care organization. American journal of managed care, 2005, 11:69-73.
20. Boshtam M et al. Obesity and associated cardiovascular risk factors in Isfahan population: Isfahan Cardiovascular Risk Factor Survey. Atheroscleroza, 1997, 1(4):7-11.
21. Lemieux I et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein b; small, dense LDL) in men? Circulation, 2000, 102: 179-84.
22. DiGirolumo M. Cellular, metabolic and clinical consequence of adipose mass enlargement in obesity. Nutrition, 1991, 7(4):287-9.
23. Campanini M et al. Lipid metabolic disorders in obesity: their epidemiology, physiopathology and clinico-therapeutic implications. Annali italiani di medicina interna, 1997, 12:223-9.
24. Watamori M et al. Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease? Diabetes research and clinical practice, 1996, 30 (Suppl.):S25-30.
25. Stratton IM et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British medical Journal, 2000, 321:405-12.
26. McKenney JM. Understanding and treating dyslipidemia associated with noninsulin-dependent diabetes mellitus and hypertension. Pharmacotherapy, 1993, 13:340-52.
27. Keller U, Golay A, Pomatto D. Dyslipidamie bei Diabetes mellitus: Bedeutung, Diagnostik und Behandlung [Dyslipidemia in diabetes mellitus: significance, diagnosis and treatment]. Schweizerische Rundschau für Medizin Praxis, 1990, 79: 1199-204.
28. Haffner SM et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Circulation, 2000, 101:975-80.
29. Ginsberg H, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. Journal of cardiovascular risk, 1999, 6(5):337-45.
30. Connelly P et al. Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obosity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group. Canadian journal of cardiology, 1999, 15(4):428-33.